Myviolet (Drospirenone, Ethinylestradiol)

Drospirenone, the active ingredient in Myviolet, is a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy in women of reproductive age by suppressing ovulation and altering cervical mucus. The formulation also contains ethinylestradiol, a synthetic estrogen that works synergistically to provide reliable contraception and menstrual cycle control.

GNH USA supplies Myviolet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Myviolet, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent unintended pregnancy.

Prevention of pregnancy: provides reliable contraception for women of reproductive age. Regulation of menstrual cycles: helps achieve more predictable bleeding patterns and reduces dysmenorrhea. Management of moderate acne: combined hormonal action can improve acne symptoms in some women.

Myviolet may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Breast tenderness - Headache - Weight gain - Mood changes - Spotting between periods

Serious or Rare Side Effects: - Venous thromboembolism (deep vein thrombosis, pulmonary embolism) - Arterial thrombosis (stroke, myocardial infarction) - Hypertension - Liver disorders (cholestasis, hepatic dysfunction) - Gallbladder disease (cholelithiasis) - Severe allergic reactions (anaphylaxis, angioedema)

Before prescribing Myviolet, clinicians should evaluate several safety considerations.

Assess cardiovascular risk: evaluate history of thromboembolic events, hypertension, or smoking. Screen for hepatic impairment: liver disease may affect hormone metabolism. Consider smoking status: advise women over 35 who smoke to avoid use. Review concomitant medications: avoid strong enzyme inducers and monitor interactions. Counsel on missed doses: provide guidance on what to do if a tablet is omitted. Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Myviolet can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Other estrogen‑containing products (e.g., hormone therapy, estrogen patches): increase risk of thromboembolic events. - Anticoagulants (e.g., warfarin): may enhance bleeding risk.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., ketoconazole, itraconazole): can increase hormone plasma levels. - Selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline): may affect bleeding patterns. - Herbal supplements such as St. John’s wort: may lower contraceptive effectiveness.